Can you beat the market with AstraZeneca plc, BAE Systems plc and ARM Holdings plc?

AstraZeneca plc (LON: AZN), BAE Systems plc (LON: BA) and Arm holdings plc (LON: ARM) could help turobocharge your portfolio’s returns.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Trying to build an equity portfolio from scratch is a daunting process. Where do you start? Well, there are three main ‘buckets’ of equities you can use to construct an all-weather portfolio that will generate steady returns over time. These three buckets are income, growth, and growth & income.

If you start at the beginning and buy one stock that falls into each one of these buckets, it’s difficult to go wrong, and you’ll have a solid portfolio backbone from which you can build out other equity positions. Here are three stocks that could be the perfect candidates.

Top income pick

When it comes to income, AstraZeneca (LSE: AZN) is a top pick. The drugs giant operates in a defensive industry and has always prioritised cash returns to investors. Indeed, dividends are so important to the company that Astra’s management compensation is linked to the company’s dividend payout. In other words, if shareholders don’t receive a set proportion of Astra’s income, then the company’s management has to take a pay cut.

For the past five years Astra’s shares have supported an average dividend yield of 4.9% and at present prices, the yield stands at 4.8%. The dividend payout is covered 1.5 times by earnings per share and Astra’s shares trade at a relatively attractive forward P/E of 14.6.

Rapid growth

BAE Systems (LSE: BA) provides the perfect blend of both growth and income. City analysts have pencilled-in a pre-tax profit of £1.5bn for 2016, and if BAE hits this target, the company will have seen its pre-tax profit grow by 270% over just four years. On a per share basis, analysts are expecting BAE to report earnings of 38.5p for the year ending 31 December 2016.

On this basis, the defence group’s shares trade at a forward P/E of 12.3. Analysts are currently expecting earnings per share growth of 7% for the year ending 31 December 2017.

What’s more, over the years BAE has built a reputation as an income champion. During the past five years the company’s shares have supported an average dividend yield of 5.1% and at current prices shares in BAE yield 4.3%. The payout is covered 1.9 times by earnings per share.

Unique growth

Astra and BAE both offer growth and income, but when it comes to a pure growth play, you can’t go wrong with Arm (LSE: ARM).

Despite concerns about the state of the semiconductor industry and flagging smartphone sales, at the end of April Arm reported a robust set of first-quarter numbers allaying worries about the company’s ability to grow in a maturing market. Revenues of $398m were up 14% year-on-year and 22% ahead in sterling terms, while pre-tax profits expanded 14% to $137.5m and earnings per share rose 15% to 8.2p, despite the fact that operating costs increased by a third. 

City analysts expect Arm’s earnings per share to grow by 43% to 34.6p overall this year, which puts the group on a forward P/E of 28.2 — its lowest valuation in five years. Arm’s shares only offer a token dividend yield of 1%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended ARM Holdings and AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young brown woman delighted with what she sees on her screen
Investing Articles

£20k to invest? 2 passive income shares to consider for a £1,880 cash boost!

The dividend yields on these FTSE 100 and FTSE 250 shares are more than double the UK blue chip average,…

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

1 artificial intelligence (AI) growth stock I’m considering buying in early 2025

This writer has been compiling a list of potential stocks to buy for his portfolio in 2025. Here's one that's…

Read more »

Investing Articles

Up 82% in 2024, could NatWest shares keep rising into 2025?

NatWest shares have been among the FTSE 100's strongest performers this year. Our writer considers why and whether he ought…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

2 dirt-cheap UK growth shares to consider for 2025!

These FTSE 250 and small-cap stocks are on sale today! And Royston Wild thinks investors seeking growth shares should give…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

Could this FTSE 250 share bounce back in 2025?

Our writer explains why one FTSE 250 share that has had a bad 2024 could see things continue poorly in…

Read more »

Investing Articles

£5,000 invested in Greggs shares at the start of 2023 is now worth…

Greggs shares have outdone the average returns of the FTSE 250 in the past two years! So how much money…

Read more »

Investing Articles

Here’s why the Rolls-Royce share price climbed 90% in 2024

What can we expect from the Rolls-Royce Holdings share price in 2025? Even more of the same, as the recovery…

Read more »

Investing Articles

Here are my top 3 stock market predictions for 2025

Based on performance this year, Jon Smith pinpoints a few different themes he feels could play out next year in…

Read more »